Skip to content

The effect vitamin C supplementation on infertile women with polycystic ovary syndrome

The comparison of the effectiveness of vitamin C supplementation with balance diet, versus Placebo on the Luteinizing hormone, follicle-stimulating hormone, Dehydroepiandrosterone, testosterone, estradiol, progesterone and sex hormone-binding protein in infertile women with polycystic ovary syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013030312672N1
Enrollment
56
Registered
2013-04-22
Start date
2012-08-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, polycystic ovarian disease. Female infertility associated with anovulation

Interventions

Intervention 1: The intervention group in the early period of hormone tests performed and then 750 mg of vitamin C per day prescribed treatment period lasted up to 22 days and then tested progesterone
Treatment - Drugs
The intervention group in the early period of hormone tests performed and then 750 mg of vitamin C per day prescribed treatment period lasted up to 22 days and then tested progesterone medication is d
The control group in the early period of hormone tests performed and then placebo prescribed treatment period lasted up to 22 days and then tested progesterone medication is discontinued. In the next

Sponsors

Shiraz University Of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: People who are willing to cooperate? Having 2 of 3 criteria Rotterdam; Women with at least one year before entering the study had tried unsuccessfully to conceive; women aged 35-18 years; Do not use alcohol; Not used hormonal drugs within the last 2 months; No abnormal bleeding; Women who still have a normal uterus and tubal; Normal Spermogram man; Disorders related to reproductive hormones; no history of pelvic surgery; The absence of Laparoscopic Surgery; Body Mass Index between 19/8 to 29 exclusion criteria: Unwillingness to continue working; sensitivity to vitamin c; abnormal bleeding.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
LH. Timepoint: Day 3 of the first menstruation, second cycle Day 3, Day 3 of the third period. Method of measurement: ELIZA.;FSH. Timepoint: Day 3 of the first menstruation, second cycle Day 3, Day 3 of the third period. Method of measurement: ELIZA.;DHEAS. Timepoint: Day 3 of the first menstruation, second cycle Day 3, Day 3 of the third period. Method of measurement: ELIZA.;Testosterone. Timepoint: Day 3 of the first menstruation, second cycle Day 3, Day 3 of the third period. Method of measurement: ELIZA.;Estradiol. Timepoint: Day 3 of the first menstruation, second cycle Day 3, Day 3 of the third period. Method of measurement: ELIZA.;Progesteone. Timepoint: Day 22 of first cycle, Day 22 of the second cycle. Method of measurement: ELIZA.;SHBG. Timepoint: Day 3 of the first menstruation, second cycle Day 3, Day 3 of the third period. Method of measurement: ELIZA.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSadigheh Forouhari

Shiraz College Of Nursing Midwifery

Forouharism@yahoo.com+98 71 1242 4128

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026